Phase III study of CC-486 as maintenance therapy in AML meets primary and key secondary endpoints Sep. 13, 2019
ADC Therapeutics studies ADCT-301 for relapsed or refractory Hodgkin's lymphoma in phase II Sep. 13, 2019
Phase III trial of Toca-511/Toca-FC in recurrent high-grade glioma misses primary endpoint Sep. 13, 2019
Phase I results of nivolumab, ipilimumab and nintedanib combination in advanced NSCLC presented Sep. 13, 2019
RSS